SCHEMBL3711901

SCHEMBL3711901

CN1CCc2c(c3cc(Cl)ccc3n2CC(=O)N2CCSCC2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 5/20 0.58
HDAC1 Q13547 5/20 0.57
HDAC6 Q9UBN7 5/20 0.57
PTGDR2 Q9Y5Y4 3/20 0.52
PTGER2 P43116 1/20 0.48
PTGDR Q13258 1/20 0.48
GRIN2B Q13224 1/20 0.44
HTR6 P50406 3/20 0.43
ADRA2A P08913 2/20 0.43
HTR2A P28223 2/20 0.43
HTR2C P28335 2/20 0.43
HTR7 P34969 2/20 0.43
ADRA1A P35348 2/20 0.43
HRH1 P35367 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.43
ACHE P22303 1/20 0.43
DRD2 P14416 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715548 0.91 BAZ2B (0.61) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL3316759 0.90 BAZ2B (0.60) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL4138385 0.89 BAZ2B (0.67) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL3713770 0.89 HTR6 (0.57) HDAC1HDAC6PTGDR2PTGDRGRIN2B
SCHEMBL13696250 0.89 BAZ2B (0.59) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL13696215 0.88 BAZ2B (0.58) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL3726830 0.88 BAZ2B (0.58) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL3724789 0.87 BAZ2B (0.57) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL4142128 0.86 BAZ2B (0.56) BAZ2BHDAC1HDAC6PTGDR2PTGER2
SCHEMBL13696218 0.86 BAZ2B (0.56) BAZ2BHDAC1HDAC6PTGDR2PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181240-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-11-10 US disclosed
US-9181240-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-11-10 US disclosed
US-9181240-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-11-10 US disclosed
US-9096591-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-08-04 US disclosed
US-9096591-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-08-04 US disclosed
US-9096591-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-08-04 US disclosed
US-20150182509-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. 2015-07-02 US disclosed
US-20150182509-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. 2015-07-02 US disclosed
US-20150182509-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. 2015-07-02 US disclosed
US-9034880-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-19 US disclosed
US-20130131054-A1 TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-8338408-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2012-12-25 US disclosed
US-8338408-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2012-12-25 US disclosed
US-8338408-B2 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. (US) 2012-12-25 US disclosed
EP-2217598-A1 NEW TETRACYCLIC COMPOUNDS Medivation Technologies, Inc. (US) 2010-08-18 EP disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
US-20090239854-A1 Tetracyclic compounds MEDIVATION TECHNOLOGIES, INC. 2009-09-24 US disclosed
WO-2009055828-A1 NEW TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2009-04-30 WO disclosed
WO-2009055828-A1 NEW TETRACYCLIC COMPOUNDS MEDIVATION TECHNOLOGIES, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150182509-A1 TETRACYCLIC COMPOUNDS HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885
US-20130131054-A1 TETRACYCLIC COMPOUNDS HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885
US-20090239854-A1 Tetracyclic compounds HTR2C, HTR3D, HTR5A BAZ2B 2213/4885HDAC1 4146/4885HDAC6 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.